Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of oral rilzabrutinib in adults with chronic immune thrombocytopenia in Japan
jRCT2031250430Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of rilzabrutinib in immune thrombocytopenia (ITP), sponsored by Sanofi. Primary endpoint: Adverse events including SAEs and AESIs. Started Oct 2025; status: active, not recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on jRCT2031250430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250430.